Compare ADMA Biologics Inc (ADMA) vs Cadence Design Systems Inc (CDNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Cadence Design Systems Inc — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Cadence Design Systems Inc trades at $371.55 (market cap $102.34B). The key difference: Cadence Design Systems Inc is far larger — about 48× ADMA Biologics Inc's market cap, and Cadence Design Systems Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | CDNS | |
|---|---|---|
Market Cap | $2.13B | $102.34B |
Sector | Health | Technology |
52-Week High | $20.38 | $416.39 |
52-Week Low | $7.60 | $265.66 |
Enterprise Value | $2.20B | $104.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Cadence Design Systems (CDNS) trades at $371.06, down 0.56% on the day, with strong analyst support showing 84% buy ratings and a $395.88 consensus price target. The stock demonstrates robust fundamentals with consistent earnings beats, 86% gross margins, and 21% net income margins. Recent technical analysis shows neutral momentum with support at $370 and resistance at $380. The company benefits from AI-driven semiconductor design demand and recently announced expanded collaboration with Intel Foundry.
CDNS presents a compelling growth story with strong profitability and market positioning in EDA software. The primary investment thesis centers on sustained AI-driven demand for chip design tools, though elevated valuation multiples (P/E 87.6) require continued execution. Key risks include semiconductor cycle volatility and competitive pressures from Synopsys. Upside potential exists if the company maintains its earnings beat streak and capitalizes on AI infrastructure spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →
